Astria Therapeutics Inc. Partners with Kaken Pharmaceutical for Phase 3 Development and Commercialization of Navenibart in Japan for Hereditary Angioedema

Reuters
08/06
<a href="https://laohu8.com/S/ATXS">Astria Therapeutics Inc</a>. Partners with Kaken Pharmaceutical for Phase 3 Development and Commercialization of Navenibart in Japan for Hereditary Angioedema

Astria Therapeutics, Inc., a biopharmaceutical company specializing in therapies for allergic and immunologic diseases, has entered into a licensing agreement with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of navenibart in Japan. Navenibart is a long-acting investigational monoclonal antibody inhibitor of plasma kallikrein, currently in Phase 3 development for the preventative treatment of hereditary angioedema $(HAE)$. Under the agreement, Astria will receive an upfront payment of $16 million, with potential additional commercialization and sales milestones totaling $16 million. The company is also eligible for tiered royalties based on net sales, reaching up to 30%, and will receive partial reimbursement for Phase 3 costs. Kaken will support the ALPHA-ORBIT Phase 3 trial, handle regulatory submissions in Japan, and share in the costs of the Phase 3 program. No results from the Phase 3 trial have been presented as of the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806414306) on August 06, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10